Hanmi Pharm shares jump 30% on Genentech obesity drug deal
Hanmi Pharm shares jump 30% on Genentech obesity drug deal
Similar Posts
The Use Cases Propelling the FedNow® Service’s Growth—and Shaping Its Future
Customers no longer measure service in days or even hours—they measure it in seconds. Whether they’re paying employees, closing on a home, moving money between accounts, or covering an unexpected expense, they expect funds to be available immediately. That demand for speed is fueling the rapid growth of real-time payments, particularly those enabled by the…
My male co-workers with kids expect me to pick up their slack because I don’t have children. Do I push back?
“They are always telling me how much harder their life is because they have kids.”
Could ageing infrastructure offer investors opportunities?
Utilities and infrastructure used to be a sector typically associated with producing steady inflation-linked income, but not now. That’s according to Jean-Hugues de Lamaze, manager of the Ecofin Global Utilities and Infrastructure Trust, who said there are strong growth prospects and a high demand for capital expenditure (Capex) in listed infrastructure. Speaking to Cris Sholton…
Down 32% or More in 2026, Are Any of These Top Cryptocurrencies Worth Buying Right Now?
Key Points Though it has taken a steep decline from its 2025 highs, XRP could rebound if the Clarity Act passes this year. Cardano continues to underperform, due to ongoing weakness in decentralized finance. The meme coin market has become extremely saturated, limiting Dogecoin’s upside potential. 10 stocks we like better than XRP › Thus…
PwC fined $4.4M for auditing missteps in UK
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. PwC faces a fine of about $4.4 million for alleged failings in its audit of British aerospace and defense firm Babcock International Group. That’s according to a news release and settlement document issued by the United Kingdom’s…
Uber Is Cutting Managers. Who Will Do the Work They Leave Behind?
The org chart shrinks. The work doesn’t.
